ProfTracy Robson

Deputy Vice Chancellor Academic Affairs

Deputy Vice Chancellor Academic Office

  • Deputy Vice Chancellor Academic Affairs
    Deputy Vice Chancellor Academic Office
  • 01-4022582 (Work)
  • RCSI, Office of the Deputy Vice Chancellor for Academic Affairs 123 St. Stephen's Green, 123 St. Stephen's Green, Dublin2 Ireland, Ireland

IMPACT AND ENGAGEMENT OVERVIEW

Professor Tracy Robson is an exceptional cancer researcher and an exemplary leader who has advanced improvements in cancer patients' journey across the island of Ireland, the UK and beyond. As a pioneer in cancer research and previous IACR President, she has been an incredibly inspiring role model for her peers and for the next generation of cancer researchers.

 

She is most passionate about supporting junior faculty in their academic careers, having supervised 37 PhD students and numerous postdoctoral staff, nine of whom have been recruited to academic positions, two to Full Professor and another three to Associate Professor. 

 

As Head of School, she was responsible for 62 academic staff whilst mentoring many more junior staff who have gone on to be awarded Wellcome Trust Fellowships, SFI SIRG, SFI Frontiers project, SFI CDAs, IRC Laureate, SFI President of Ireland Future Research Leader Award, USA Susan Komen Challenge grant and have been promoted from Lecturer to Senior Lecturer, Associate Professor & Professor.

 

Professor Cathal Kelly, Vice Chancellor of RCSI, said: “Professor Robson has advanced the development of potential treatments for end stage ovarian cancer where there is a significant unmet clinical need. Her important contributions to cancer research have garnered substantial funding to ultimately make this critical work a reality for patients. As our Deputy Vice Chancellor for Academic Affairs, she is an inspiration to our academic staff and her vision and leadership has paved the way for the next generation of cancer researchers.”

IMPACT & ENGAGEMENT

  • RESEARCH IMPACT
    Lead contributors for this impact or engagement:
    • Robson T
    ALM201 – Orphan Drug Designation Granted in Ovarian Cancer
  • INDUSTRY & INNOVATION IMPACT
    Breast Cancer Now and MRC UK funding lead to licensed patent
    Lead contributors for this impact or engagement:
    • Robson T
    This funding allowed the development of FKBPL as a prognostic breast cancer biomarker and a predictive marker of response to endocrine therapy. This led to filing of patent (WO/2010/133880) which was then licensed to Almac Discovery, enhancing their commercial competitiveness and economic impact.
  • EDUCATION, ACCESS AND WIDENING PARTICIPATION
    Lead contributors for this impact or engagement:
    Professor Robson successfully led the bid as Principal Investigator to secure €7.8 million in education grants from the Higher Education Authority, Human Capital initiative, Pillar 3 to deliver focused programmes designed to meet priority skill needs for enterprise. Human Capital Initiative Pillar 3, 'Innovation and Agility', is the final pillar to be announced and commands a total budget of €197m over the five-year period, 2020 to 2025. The Human Capital Initiative Pillar 3 will deliver 22 projects in higher education institutions, 17 of which involve collaborations between institutions.
  • SOCIETAL IMPACT - AWARDS OR DISTINCTIONS
    Lead contributors for this impact or engagement:
    • Robson T
    The Irish Association for Cancer Research (IACR) Outstanding Contribution to Cancer Medicine and Research Award for 2025 has been awarded to Professor Tracy Robson. The award recognizes her leadership in cancer research in Ireland, particularly her work advancing potential treatments for ovarian cancer and her success in securing over €15 million in research grants
  • EDUCATION, ACCESS AND WIDENING PARTICIPATION
    Lead contributors for this impact or engagement:
    • Robson T
    In 2023, Professor Robson successfully led the bid to secure a €1.2 million investment from the HEA which supported the enhancement of educational facilities to create a high-tech science laboratory with capacity for 142 students.
  • EDUCATION, ACCESS AND WIDENING PARTICIPATION
    Lead contributors for this impact or engagement:
    • Robson T
    Professor Robson successfully led the bid to secure funding support from the Department of Further and Higher Education, Research, Innovation and Science (DFHERIS) The revised MPharm, underpinned by innovative approaches, continues to be implemented with the introduction of two additional modules in Lifestyle Medicine and Sustainability furthering the school’s commitment to embedding sustainability and, along with these modules, has led to incorporated aspects of climate change and the environmental threats of healthcare into the Global Public Health Module also. As a result, an additional 15 CAO students were enrolled in the MPharm in 2023 alone.